Geneuro Logo

Geneuro

GEM | PA

Overview

Corporate Details

ISIN(s):
CH0308403085
LEI:
213800FUJCKXO9LK3444
Country:
Switzerland
Address:
chemin du Pré-Fleuri 3, 1228 Plan-les-Ouates
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

GeNeuro is a Swiss-based, clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative and autoimmune diseases. The company utilizes a novel therapeutic approach that targets pathogenic proteins encoded by human endogenous retroviruses (HERVs), which are believed to contribute to the progression of diseases such as Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), and post-COVID conditions. Its main drug candidate, temelimab, is being developed to treat the cognitive and fatigue symptoms associated with Long COVID. In July 2024, the company was granted a debt-restructuring moratorium.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Geneuro. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-06-30 19:37
Post-Annual General Meeting Information
Inside Information / Other news releases
English 224.5 KB
2025-06-30 19:37
Post-Annual General Meeting Information
Informations privilégiées / Autres communiqués
French 753.1 KB
2025-06-12 22:42
Legal Proceedings Report
Inside Information / Other news releases
English 204.9 KB
2025-06-12 22:42
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 203.8 KB
2025-06-10 18:24
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 207.4 KB
2025-06-10 18:24
Pre-Annual General Meeting Information
Inside Information / Other news releases
English 209.5 KB
2025-05-27 18:00
Legal Proceedings Report
Inside Information / Other news releases
English 162.5 KB
2025-05-27 18:00
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 187.1 KB
2025-05-12 18:36
Report Publication Announcement
Inside Information / Other news releases
English 481.8 KB
2025-05-12 18:36
Report Publication Announcement
Informations privilégiées / Autres communiqués
French 669.5 KB

Automate Your Workflow. Get a real-time feed of all Geneuro filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Geneuro via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Medicofarma Biotech Spolka Akcyjna Logo
Biotech R&D firm developing novel drugs, devices, and therapies with a focus on oncology.
Poland MDB
Medigene AG Logo
An immuno-oncology platform creating T cell receptor (TCR)-guided therapies to treat cancer.
Germany MDG1
MedinCell S.A. Logo
Develops and licenses long-acting injectable therapies using proprietary technology.
France MEDCL
Medivir Logo
Clinical-stage pharma firm developing tumor-directed therapies for high-need cancer patients.
Sweden MVIR
Mendus Logo
Developing immunotherapies using dendritic cells to prevent recurrence of AML & ovarian cancer.
Sweden IMMU
Merck KGaA Logo United States of America 6MK
Sweden MBOLIC
Milton Essex Spolka Akcyjna Logo
Develops AI-powered, non-invasive systems for allergy diagnostics & personalized medicine.
Poland MTN
Modus Therapeutics Holding AB Logo
Clinical-stage biotech developing sevuparin for sepsis, septic shock, and inflammation.
Sweden MODTX
Molecular Partners AG Logo
Pioneering DARPin protein drugs for complex diseases in oncology and virology.
Switzerland MOLN